A/Prof Mary Ann Anderson
Honorary Conjoint Principal Fellow
The Sir Peter MacCallum Department of Oncology
189 Scholarly works
1 Projects
HIGHLIGHTS
2022
Journal article
Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy
DOI: 10.1182/blood.20220160402022
Journal article
Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL
DOI: 10.1182/blood.20210127752022
Research grants (other domestic)
Novel Strategies to Predict and Monitor Response to CAR T-Cell Therapy in DLBCL
2021
Journal article
Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition
DOI: 10.1182/bloodadvances.20210050832021
Journal article
Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy
DOI: 10.1182/blood.20200095782020
Journal article
BAX-Mutated Clonal Hematopoiesis in Patients on Long-Term Venetoclax for Relapsed/Refractory Chronic Lymphocytic Leukemia
DOI: 10.1182/blood-2020-1377752020
Journal article
Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax
DOI: 10.1182/BLOOD.2019004205
RECENT SCHOLARLY WORKS
2026
Journal article
Richter transformation: emerging immunologic strategies beyond chemoimmunotherapy.
DOI: 10.1182/bloodadvances.20260201972026
Journal article
Marginal zone lymphoma is associated with dysregulated T-cell immunity that is not altered by ibrutinib-venetoclax treatment
DOI: 10.1016/j.bneo.2026.1002602026
Journal article
A Structured Approach for Treatment Selection in Chronic Lymphocytic Leukemia: A Multiregional Expert Consensus
DOI: 10.1016/j.bglo.2026.1001482026
Journal article
Australasian chronic lymphocytic leukaemia consensus statement: 2026 update
DOI: 10.1111/imj.705032026
Journal article
EXABS-206-CLL: Bringing Order to the Alphabet Soup in Chronic Lymphocytic Leukemia Treatment
DOI: 10.1016/s2152-2650(26)00331-92026
Journal article
Long-term outcomes with continuous venetoclax for relapsed chronic lymphocytic leukemia.
DOI: 10.1182/bloodadvances.20260207892026
Journal article
Frontline CLL: lessons from the final analysis of CLL13-GAIA
DOI: 10.1182/blood.20260337772026
Journal article
Effect of first-line treatment of CLL/SLL with the all-oral combination of sonrotoclax (sonro) and zanubrutinib (zanu) on minimal residual disease (uMRD) rates, including in patients with del(17p)/TP53.
DOI: 10.1200/jco.2026.44.16_suppl.7043